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In the present review, we deliver an overview of the involvement of metabotropic
glutamate receptor 5 (mGluR5) activity and density in pathological anxiety, mood
disorders and addiction. Specifically, we will describe mGluR5 studies in humans
that employed Positron Emission Tomography (PET) and combined the findings
with preclinical animal research. This combined view of different methodological
approaches—from basic neurobiological approaches to human studies—might give a
more comprehensive and clinically relevant view of mGluR5 function in mental health
than the view on preclinical data alone. We will also review the current research data
on mGluR5 along the Research Domain Criteria (RDoC). Firstly, we found evidence
of abnormal glutamate activity related to the positive and negative valence systems,
which would suggest that antagonistic mGluR5 intervention has prominent anti-addictive,
anti-depressive and anxiolytic effects. Secondly, there is evidence that mGluR5 plays an
important role in systems for social functioning and the response to social stress. Finally,
mGluR5’s important role in sleep homeostasis suggests that this glutamate receptor may
play an important role in RDoC’s arousal and modulatory systems domain. Glutamate
was previously mostly investigated in non-human studies, however initial human clinical
PET research now also supports the hypothesis that, by mediating brain excitability,
neuroplasticity and social cognition, abnormal metabotropic glutamate activity might
predispose individuals to a broad range of psychiatric problems.
Keywords: mGluR5, PET, mood disorders, addiction, anxiety
Introduction
Glutamate is the primary excitatory neurotransmitter in the brain, and numerous researchers
have suggested that it plays a significant role in various mental health and medical condi-
tions. Indeed, researchers often mention the potential of developing ionotropic or metabotropic
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glutamate-based pharmacological treatment for numerous psy-
chiatric disorders, in the form of either agonists or antago-
nists. Knowledge about the glutamatergic system has greatly
advanced in the last decade, which has resulted from techno-
logical advances in receptor and transmitter imaging in humans.
Even though there are a large number of experimental studies on
glutamate intervention in various psychiatric disorders, there is
a lack of systematic reviews that focus on combining the results
of preclinical animal research studies with other neuroscience
methods, such as human Positron Emission Tomography (PET).
Thus, compared to previous reviews (Swanson et al., 2005; Pit-
tenger et al., 2006; Kalivas, 2009; Brennan et al., 2012; Luykx et al.,
2012; Riaza Bermudo-Soriano et al., 2012), this review examines
human studies, mostly PET research, and combines those results
with preclinical findings.
Positron Emission Tomography (PET)
PET is a nuclear, sensitive, and non-invasive medical imaging
technique used to image receptor distribution, concentration,
and function. To identify human brain receptors, radio labeled
receptor ligands (tracers) need to be developed. The scanner
device detects gamma rays emitted by the tracer, which is intro-
duced into the body. An mGluR5 PET tracer suitable for human
studies was successfully developed at the Paul Scherrer Institute
(PSI) in Villigen, Switzerland, and the Swiss Federal Institute
of Technology (ETH) in Zurich, Switzerland. ABP688 is a non-
competitive and highly selective antagonist, which binds to an
allosteric site of the mGluR5. 11C-ABP688 showed high selectiv-
ity for mGluR5 and high uptake in receptor-rich brain regions.
The first description of these characteristics of 11C-ABP688 in
animals is previously published (Ametamey et al., 2006).We have
seen promising results from studies performed in rats that use a
beta-probe to estimate the kinetics of this tracer. Furthermore,
when we performed the first PET study in humans to estimate
the kinetics in humans (Ametamey et al., 2006) we found results
comparable to those found in rat studies (Soares and Law, 2009).
We have now successfully used the developed tracer for research
on mGluR5 in healthy volunteers and psychiatric patients. PET
techniques deliver information about the relative density of the
receptors within the brain area examined. There is no informa-
tion regarding the concentration of the neurotransmitter (i.e.,
whether high receptor density might lead to or be the conse-
quence of increased or reduced neurotransmitter action). PET
research delivers information regarding receptor level abnor-
malities in living human patients and thus helps to evaluate
which receptors should be targeted with pharmaceutical treat-
ment. On the contrary, Magnetic Resonance Spectroscopy (MRS)
provides in vivo biochemical information about the tissue exam-
ined (Hasler et al., 2009) and thus provides information regarding
the relative amount of glutamate metabolite in groups of patients.
Findings from PET and MRS research can deliver additional evi-
dence to pre-clinical animal studies. Animal research is the state
of the art preclinical research method. Various animal models
of psychiatric conditions have been established. Animal studies
allow testing mechanical models, and testing of new pharmaceu-
ticals in these models to reduce potential harm to humans. One
disadvantage for animal research in psychiatry might, however,
lie in the development of suitable animal models for different
psychiatric conditions, specifically, conditions that involve inter-
nal or unique human cognitive aspects might lead to problems.
Thus, a new pharmaceutical that shows improvement in animal
behavior might not help human internal psychological aspects of
the psychiatric condition.
This paper will thus examine if the findings from preclinical
research in animals and human psychiatric PET research form a
coherent view of mGluR5 involvement in mental disorders. This
review will discuss only mGluR5 activity because extensive PET
human data are available for this receptor type. mGluR5 delivers
a promising target for drug development because a PET tracer
can measure mGluR5 binding in humans, thus providing further
insight into its functions in humans. Indeed, research suggested
that drugs targeting the metabotropic glutamate group I recep-
tors are among the most promising agents currently under devel-
opment for the treatment of psychiatric conditions (Krystal et al.,
2010).
In this review, we start with a brief introduction of the gluta-
mate system and mGluR5, and then proceed to evaluate mGluR5
involvement in anxiety and mood disorders, and addiction by
comparing previous preclinical trials with recent PET studies.We
will then describe an approach how mGluR5 based interventions
might be efficient by contributing to changes in learning and
social functioning, and by decreasing excitability within various
brain regions.
The Glutamatergic System and mGluR5
Glutamate regulates central nervous system function through the
actions of ionotropic and metabotropic receptors. The involve-
ment of glutamate in various psychiatric and medical condi-
tions has been intensively examined. However, earlier work
mostly focused on ionotropic glutamate receptors. In contrast
to the fast and direct actions of ionotropic receptors, the three
groups of metabotropic (mGlu) receptors modify neuronal activ-
ity through G-protein coupled signaling. Groups of mGluRs are
distinguished by their pharmacological and intracellular signal-
ing properties. mGluR5, which was first cloned in animals in 1992
and a few years later in humans, belongs to group I metabotropic
receptors (Olive, 2005). Its actions are predominantly excitatory
(Meldrum, 2000). Cleva and Olive (2011) described strong links
and receptor interactions between mGluR5 and NMDA recep-
tor, suggesting that mGluR5 might also be extensively implicated
in mediating neural plasticity as well as learning and memory
processes. In addition, there is some evidence that mGluR5
activation enhances GABA, especially in the nucleus accum-
bens (Hoffpauir and Gleason, 2002). Thus, it is suggested that
metabotropic glutamate receptor activity can modulate excita-
tory and inhibitory (GABA) signaling pathways. High mGluR5
receptor density was identified primarily in the forebrain regions,
striatum, and limbic regions including the amygdala and hip-
pocampus (Swanson et al., 2005). Using advanced molecular bio-
logical techniques to determine mGluR5 mRNA expression in
the rodent brain, research determined that regions of the olfac-
tory bulb, dorsal striatum, nucleus accumbens, lateral septum,
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and hippocampus show the highest levels of mGluR5 expression
(Abe et al., 1992) (See Figure 1).
Pre-synaptic mGluR5 receptors were found to participate in
the regulation of synaptic plasticity and changes in neuronal
excitability to maintain homeostasis (Schoepp, 2001). Impor-
tantly, significant mGluR5 expression can already be determined
at 9 Gestational Week (GW) prenatal (Boer et al., 2010). Addi-
tionally, mGluR5 expression was found to be much higher in
younger animals than in adults (Romano et al., 1996), suggest-
ing that early intervention targeting the mGluR5 might have
preventive effects in neurodevelopmental disorders.
Because of its functions in different neuronal processes, gross
abnormalities in the glutamate system lead to severe neurological
impairment (e.g., seizure disorder), whereas smaller changes can
contribute to various psychiatric conditions (Yüksel and Öngür,
2010). Efforts to develop drugs that selectively target mGluR5
began in the late 90s. To date, various mGluR5 agonists and
antagonists have been developed (See Lea and Faden, 2006 for
further information regarding specific drug development). For
example, 3-[2-methyl-1,3-thiazol-4yl]ethynyl]pyridine (MTEP)
is a highly selective and potent non-competitive mGluR5 recep-
tor antagonist that achieves full receptor occupancy 1 h after
injection in rats with a dose of 10mg/kg (Anderson et al., 2003).
FIGURE 1 | Localization of mGluR5 mRNA in the adult and the
6-day-old rat brains by in situ hybridization. Negative film images of
sagittal section of the adult rat brain (A) and the 6-day-old rat brain (B) are
shown. OB, main olfactory nucleus; Ac, accumbens nucleus; Tu, olfactory
tubercle; St, striatum; Hi, hippocampus; S, subiculum; Cx, cerebral cortex; LS,
lateral septal nucleus; IC, inferior colliculus; Cb, cerebellar cortex; Sp, spinal
trigeminal nucleus; T, thalamus; VMH, ventromedial hypothalamic nucleus.
Scale bar, 4mm. From Abe et al. (1992). Note: the figure and its legend is
reproduced with permission.
Table 1 gives an overview of somemGluR5 drugs used in animals
and those previously used in the initial clinical human trials.
Psychiatric Disorders and Glutamate
Based Intervention in Humans
Psychiatric disorders are very heterogeneous and co-morbidity
is common. However, common psychiatric pharmacological
treatments are based on relatively few pathophysiological mech-
anisms, for example, increasing monoamine availability in anx-
iety and depression. Thus, there is an urgent need to improve
and advance psychiatric treatments, and metabotropic glutamate
based pharmacological intervention is a promising development
in this regard (Agid et al., 2007).
Most human trials have been conducted on cases of Fragile
X Syndrome (FXS). The mGluR5 theory of FXS posits that the
lack of fragile X mental retardation protein (FMRP) results in
excessive glutamatergic signaling via mGluR5 (Bear et al., 2004).
This leads to increased local mRNA translation at the synapse
because FMRP is not present to regulate the process. Finally,
this weakens the synapse and results in an increased number of
longer immature dendritic spines, which could explain the intel-
lectual disability found in FXS patients. This disability is associ-
ated with mood and anxiety symptoms and typically present with
features that are common in autism spectrum disorder, includ-
ing delays in speech and language development, impaired the-
ory of mind, and impaired social and emotional processing, as
well as repetitive behavior (Garber et al., 2008). Preliminary and
indirect evidence that mGluR5 antagonist can improve sociabil-
ity in FXS (Burket et al., 2014) raises hopes that drugs target-
ing the mGluR5 might be of clinical use in prevalent psychiatric
conditions associated with impaired systems for social processes
such as autism, schizophrenia, and depression. Furthermore, the
observable repetitive behavior phenotype in FXS might suggest a
shared pathophysiology among other psychiatric disorders such
as obsessive-compulsive disorder (OCD) and addiction.
Although there has been an increase in the scientific knowl-
edge and research on mGluR5, drug development efforts have
been relatively unsuccessful (Agid et al., 2007). Drugs that tar-
get the ionotropic receptors usually produce numerous side
effects and current drug development strategies have not yet
produced selective targets for ionotropic receptors that might
reduce potential side effects. For instance, ionotropic receptor
TABLE 1 | Selection of mGluR5 acting pharmaceuticals.
mGluR5 Drug Mechanism Usage References
MTEP mGluR5 antagonist Animal research e.g., Gass et al., 2009;
Koros et al., 2007
Acamprosate mGluR5 antagonist Human trials e.g., Erickson et al.,
2011
Memantine mGluR5 antagonist Human trials e.g., Erickson et al.,
2009
AFQ056 mGluR5 antagonist Human trials e.g., Berg et al., 2011
Fenobam mGluR5 antagonist Human trials e.g., Berry-Kravis et al.,
2009
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antagonists produce side effects in humans that include mem-
ory impairment, psychotic episodes, and strokes (Swanson
et al., 2005). The unfavorable side effects might occur because
ionotropic glutamate receptors have a ubiquitous distribution,
whereas metabotropic receptors are more uneven and selec-
tively distributed (Krystal et al., 2010). As a result, recent drug
development has focused on compounds targeting metabotropic
receptors assuming that such drugs will be associated with fewer
side effects than those that bind to the fast-acting ionotropic
receptors.
In the following sections, we will review evidence from human
PET studies regarding mGluR5 involvement in mood disorders
and addiction and compare those findings to animal studies.
Additionally, we will describe some brain locations for mGluR5
activity in humans and finally suggest an approach how direct
and indirect mGluR5 activity might be involved in human psy-
chiatric syndromes.
mGluR5, Pathological Anxiety, and Mood
Disorders
Pathological Anxiety
Pathological anxiety occurs in anxiety disorders, including gen-
eralized anxiety disorder, panic disorder (the most prevalent psy-
chiatric conditions worldwide, First and Gibbon, 1997), but also
in other prevalent psychiatric conditions such as depression and
obsessive-compulsive disorder (OCD). These psychiatric condi-
tions cause significant impairment in both social and occupa-
tional functioning, leading to health cost burdens and patient
suffering (First and Gibbon, 1997). Generally, anxiety might be
associated with excessive brain excitability (Harvey and Shahid,
2012).
Preclinical Neurobiological Research
Findings from a large number of preclinical animal trials have
determined the effect of mGluR5 antagonist treatment in anx-
iety. Swanson et al. (2005) reviewed animal studies on drugs
targeting the mGluR5 on anxiety-like behaviors. They con-
cluded that mGluR5 antagonistic treatment mostly led to anx-
iolytic responses in experimental animals. In particular, effects
such as reduced fear conditioned freezing, increased shock
and punishment acceptance, and increased social interactions
were observed. For example, a single dose of 2-methyl-6-
(phenylethynyl)pyridine (MPEP) increased the amount of time
that rats spent in the open arm of an experimental maze, with-
out affecting planning or motor behavior (Tatarczyn´ska et al.,
2001). Krystal et al. (2010) reviewed preclinical animal studies
that examined mGluR5 antagonists (MTEP, MPEP, fenobam) in
mouse models of anxiety. These studies used different outcome
measures, such as extinction of fear conditioning and responses
in the elevated plus maze, to assess the effectiveness of drug
treatments. Of the studies examined, 88.45% reported an anxi-
olytic effect with mGluR5 antagonists (Krystal et al., 2010). More
recently, another review on anxiety research in animal models
that examined the effect of ionotropic and metabotropic glu-
tamate receptor antagonist intervention was published (Riaza
Bermudo-Soriano et al., 2012). Regarding mGluR5, the authors
listed 43 animal studies of anxiety, and all but two demonstrated
anxiolytic effects.
Human Studies
Initial evidence for the hypothesis that glutamate function is
abnormal in anxiety disorders came from MRS research. For
instance, using single-voxel high-field 1H-magnetic resonance
spectroscopy, the researchers found that compared to healthy
controls, patients with social anxiety disorder showed signifi-
cantly higher glutamate levels in the anterior cingulate cortex
(ACC) (Phan et al., 2005). Additionally, research found increased
global glutamate concentration in 10 patients with social phobia
(Pollack et al., 2008). As stated before, these studies, however,
could not determine which glutamate receptors were associated
with excessive glutamate activity.
Employing PET research methodology, we recently were the
first to show relationships between mGluR5 and anxiety, in
Major Depressive Disorder (MDD), and OCD. In one study,
we researched mGluR5 Distribution Volume Ratio (DVR) in 10
patients with OCD and 10 healthy controls using [11C]ABP688
PET (Akkus et al., 2014). We employed the Yale-Brown
Obsessive-Compulsive Scale (Y-BOCS) as a clinical measure of
OCD symptom severity. We observed significant positive cor-
relations between Y-BOCS obsession scores and mGluR5 DVR
in regions of the amygdala, ACC, and medial orbitofrontal cor-
tex (Akkus et al., 2014). These brain areas have previously been
implicated in OCD pathophysiology. Indeed, structural brain
abnormalities in the amygdala, the ACC, and the orbitofrontal
cortex consistently have been associated with OCD (Rosenberg
and Keshavan, 1998; Szeszko et al., 2008; Van den Heuvel et al.,
2009). Given that structural imaging studies have provided evi-
dence for a positive correlation between OCD severity and gray
matter volume (Zarei et al., 2011), increased mGluR5 binding
in OCD may reflect an increased density of neurons. Although
in DSM-5 OCD is not considered anymore as an anxiety dis-
order, most OCD patients experience anxiety symptoms. In a
relatively large clinical sample, we have previously shown that
OCD patients with obsessions have a particularly high prevalence
of anxiety symptoms and disorders (Hasler et al., 2005). In this
paper, we suggested that obsessions that involve stress, anxiety,
or conflict thus might be associated with increased glutamater-
gic neurotransmission in the amygdala, ACC, and orbitofrontal
cortex.
Taken together, the findings from recent studies using dif-
ferent research methodologies support the hypothesis that glu-
tamate function is abnormal in key areas of the limbic system
in mood disorders related to anxiety. The abnormal function
is likely to also be related to the mGluR5 receptor. Since, pre-
clinical, as well as PET research showed a consistent pattern of
results, we suggest that antagonistic mGluR5 treatment would
produce significant anxiolytic effects in patients suffering from
pathological anxiety.
Major Depressive Disorder (MDD)
Preclinical Neurobiological Research
In their review, Krystal et al. (2010) described the outcomes of
eight studies investigating the mGluR5 antagonists MTEP and
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MPEP in animal models of depression. Compared to the treat-
ment success rates for anxiety disorders, the authors reported that
only 62.5–75% found a clear antidepressant effect, even though
treatment with the ionotropic NMDA antagonist ketamine has
been shown to lead to rapid antidepressant effects, even in
treatment resistant patients (Pittenger et al., 2006).
Human Studies
A recent review reviewed 13MRS studies of mood disorders. The
authors reported that these studies consistently found evidence
that glutamate was reduced in MDD (Hasler et al., 2007; Yüksel
and Öngür, 2010). In particular, reduced glutamate levels in the
ACC, left dorsolateral prefrontal cortex, dorsomedial prefrontal
cortex, ventromedial prefrontal cortex, amygdala, and hippocam-
pus were found. A later review on studies that used MRS to
examine glutamate in MDD confirmed that glutamate concen-
tration in the ACC was consistently reduced (Luykx et al., 2012).
In the occipital cortex, increased glutamate were found by some
researchers, which were highest in the melancholic subgroup of
patients with MDD (Sanacora et al., 2008).
In a previous study, we obtained PET images of mGluR5
receptor binding in 11 unmedicated subjects with MDD and 11
healthy controls (Deschwanden et al., 2011). We found decreased
regional mGluR5 binding in the prefrontal cortex, cingulate cor-
tex, insula, thalamus, and hippocampus of the patients suffer-
ing from depression. Additionally, the severity of depression
negatively correlated with mGluR5 binding in the hippocam-
pus. We suggested that these findings indicate reduced mGluR5
neurotransmission in depression, possibly as a result of basal
or compensatory changes in the glutamate system activity. In
addition, we examined the amount of mGluR5 expression in
post-mortem brain samples of 15 depressed subjects and 15
matched controls (Deschwanden et al., 2011). We observed
reduced mGluR5 expression in the prefrontal cortex in samples
obtained from depressed individuals. Reduced NMDA receptor
expression in the post-mortem brain of depressed patients also
was reported (Feyissa et al., 2009). Indeed, it was previously sug-
gested that the antidepressant properties of mGluR5 antagonists
may involve inhibition of NMDA receptor. This might medi-
ate neurotransmission and/or induction of brain-derived neu-
rotropic factor gene expression in the hippocampus (Legutko
et al., 2006). Further, a recent study showed that sleep depriva-
tion increasesmGluR5 availability in healthy humans (Hefti et al.,
2013). In anterior cingulate cortex, insula, medial temporal lobe,
parahippocampal gyrus, striatum, and amygdala, this increase
correlated significantly with the efficacy of sleep deprivation as
reflected by increased subjective sleepiness. This study suggests
that an increase in mGluR5 may be a neurobiological mecha-
nism explaining sleep deprivation’s high antidepressant efficacy.
Preclinical studies confirm our hypothesized association between
mGluR5, sleep and depression. In particular, a study in mGluR5
knock-out mice provides important evidence that mGluR5 is
involved in shaping the stability of NREM sleep-REM sleep state
transitions, NREM slow wave activity and homeostatic response
to sleep loss (Ahnaou et al., 2015).
To summarize, there is convergent evidence from animal,
postmortem, MRS, and PET studies that the central glutamate
system is importantly involved in the pathophysiology of MDD.
However, the evidence suggests that mGluR5 antagonism might
not directly help patients suffering from MDD. This is in accor-
dance with our finding of reduced mGluR5 expression in MDD
patients. It could be speculated that drugs that target the mGluR5
system may be particularly useful in depressed patients with
comorbid anxiety, addiction disorders and/or impaired circadian
rhythms. Further, impairments in the systems for social pro-
cesses are commonly associated with MDD. Poor social skills
have appeared to be an important risk factor for depression (Seg-
rin, 2000). Such deficits including paralinguistic and linguistic
behaviors, and impairments in facial expression, gaze, posture
and gesture, that are comparable to those observed in FXS and
autism spectrum disorder. Furthermore, regarding social skills,
experiments in mice exposed to chronic social stress showed
that Homer1/mGluR5 coupling was disrupted, suggesting that
mGluR5 night moderate the depressive vulnerability to social
stress (Wagner et al., in press). Additionally, in mouse models
of social deficits, mGluR5 suppression has led to normalization
of social interactions (Chung et al., 2015). Together, these studies
provide preclinical evidence that mGluR5 plays important roles
in the social causes of depression and the social deficits frequently
observed in depressed patients. As a result, drugs targeting the
mGluR5 may play an important role to prevent the develop-
ment of depression in youth with social deficits and may help to
treat social deficits and low psychosocial functioning in patients
with MDD.
mGluR5 and Addiction
Addiction is characterized by continued drug intake despite neg-
ative consequences, repeated unsuccessful attempts to stop or
reduce drug use, and symptoms of tolerance and withdrawal.
Although the dopamine system plays a key role in acute reward
processing (Kalivas and Volkow, 2005), there is growing evi-
dence implicating glutamatergic neurotransmission in addiction
(Krystal et al., 2010).
Preclinical Neurobiological Research
In 2001, a seminal study on mGluR5 and addiction was pub-
lished (Chiamulera et al., 2001). The authors showed that
mice lacking the mGluR5 receptor failed to acquire intravenous
cocaine self-administration despite showing increased extracel-
lular dopamine levels in the nucleus accumbens following acute
injection. Numerous follow-up animal studies have demon-
strated that the mGluR5 receptor antagonists MPEP and MTEP
reduce self-administration of addictive drugs such as cocaine
and nicotine (Kalivas, 2009). Olive (2005) reviewed animal stud-
ies related to drug addiction and suggested that there is evi-
dence that mGluR5 might be involved in development, reward
perception, and relapse of drug use such as that of cocaine,
morphine, nicotine, and ethanol. The authors described evi-
dence from animal studies that mGluR5 antagonists reduced self-
administration of the drug, as well as subsequent drug-seeking
behavior. For example, recently, it was discovered in a baboon
model of binge-eating disorder that MTEP decreased candy con-
sumption without altering candy-seeking behavior (Bisaga et al.,
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2008). Research suggested that the decrease of food intake asso-
ciated with mGluR5 receptor antagonist use might be related
to a reduction in the rewarding value of the reinforcing stimuli
(Bisaga et al., 2008). Additionally, research reported significant
increases in mGluR5 mRNA levels in the nucleus accumbens
and dorsolateral striatum after repeated cocaine administration
in experimental rats (Bisaga et al., 2008).
Human Studies
Using autoradiography in post-mortem brain tissue samples
obtained from patients suffering from alcohol disorders and
healthy controls, research found 30–40% higher mGluR1/5 bind-
ing density in the hippocampus and striatum in patients suffering
from alcohol disorders (Kupila et al., 2012). This finding sug-
gested that mGluR5 receptor density might be increased in some
brain areas of alcohol-addicted patients. Recently, we used PET
to measure mGluR5 receptor binding in the brains of individuals
with nicotine addictions (Akkus et al., 2013). We found a global
reduction in mGluR5 DVR in the gray matter of 14 smokers
compared to non-smokers (See Figure 2). The most prominent
reductions were found in the right and left medial orbitofrontal
cortex. We suggested this decrease in mGluR5 receptor binding
might be a long-lasting adaptation to chronic increases in gluta-
mate induced by chronic nicotine administration. This adapta-
tion seems to be specific for nicotine dependence since it has not
been found in chronic non-smoking cocaine users (Hulka et al.,
2014).
Indeed, it has been suggested that mGluR5 downregulation
represents a compensatory neuroadaptation (Kalivas, 2009), an
enhancer of drug-induced reward (Rutten et al., 2011), or a factor
mediating the effects of contextual cues in conditioned behavioral
FIGURE 2 | Image display the average brain uptake of mGluR5 DVR in
the three diagnostic groups. The brain uptake is visible reduced in smoker
and ex-smokers groups. Images are calculated by PMOD software version 3
(PMOD Technologies). From Akkus et al. (2013). Note: the figure and its legend
is reproduced with permission.
responses (Tronci et al., 2010). Figure 3 presents an approach of
mGluR5 dysfunction in addiction.
As seen in Figure 3, previous research supports the idea
that mGluR5 is involved in three key stages of addiction, in
the development and acquisition, in the reinforcement value
of the drug, as well as in addiction relapse. It might be sug-
gested that each function is predominantly described by differ-
ent brain regions, which also show high mGluR5 receptor den-
sity, and which have been shown to display reduced mGluR5
density in our PET research (Deschwanden et al., 2011). Kali-
vas (2009) developed an extensive glutamate model of addic-
tion. The author suggested that addiction was associated with
dysfunction in glutamate homeostasis between key areas of the
corticostriatal brain circuitry, including the amygdala, nucleus
accumbens (NA), prefrontal cortex, andmotor cortex. As we sug-
gest in Figure 3, firstly (“Motivation component”), the prefrontal
cortex might mediate motivation and cognitive control during
the initial phases of drug addiction development. The preclin-
ical study by Chiamulera et al. (2001) suggests that mGluR5 is
required in this phase of addiction development by mediating
the rewarding properties of drugs of abuse. Secondly (“Reward
component”), the Nucleus Accumbens (NA) has been shown to
influence the rewarding value of the drug, not only via dopamine
but also via mGluR5 activity (Bisaga et al., 2008). In particu-
lar, impairment in glutamate transmission between the prelim-
bic cortex and the NA was suggested, such that drug seeking
was initiated by a greater reliance on learned behavior associated
with the NMDA/mGluR5 receptor system (Kalivas, 2009). And
thirdly (“Drug Seeking component”), some research supports
that mGluR5 is involved in higher reliance on motor processes—
reducing cognitive control—via striatum (Kupila et al., 2012).
Our own published and unpublished research suggests that
mGluR5 downregulation is associated with increased risk of
relapse in ex-smokers (Akkus, PNAS). This downregulation may
be a pathogenic or an insufficient compensatory change. Taken
together, the current research suggests that drugs targeting the
mGluR5 may improve treatments of addiction disorders in vari-
ous stages of their development.
Discussion
The reviewed evidence suggests high involvement of mGluR5
within anxiety disorders, OCD, MDD, as well as addiction, and
that treatment with mGluR5 targeting pharmaceuticals might be
beneficial also in humans. However, the pathogenesis of mood
and anxiety symptoms associated with OCD may differ from
mood and anxiety symptoms unrelated to OCD. As a result, the
presence of obsessive-compulsive symptoms may be an impor-
tant predictor of the antidepressant and anxiolytic response to
drugs targeting the mGluR5. Furthermore, we have suggested
that drugs targeting the mGluR5 system may help to increase
resistance to social stress and improve social deficits in depres-
sion. Since social stress is by far the most important non-genetic
risk factor of depression and social deficits are closely linked
to reductions in social functioning and quality of life, these
findings from animal studies are of high scientific and clinical
relevance.
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FIGURE 3 | mGluR5 involvement in addiction.
Recently, the National Institute of Mental Health (NIMH)
has initiated a novel, state-of-the art project: The Research
Domain Criteria (RDoC). This reflects the implementa-
tion of NIMH Strategy 1.4 “Develop, for research purposes,
new ways of classifying mental disorders based on dimen-
sions of observable behavior and neurobiological measure.”
(http://www.nimh.nih.gov/research-priorities/strategic-objectiv
es/strategic-objective-1.shtml). This initiative was the results of
restructuring rigid DSM categories, most of which were also
developed before neuroscience research (Morris and Cuthbert,
2012). RDoC describes five domains or constructs; Negative
valence system, Positive valence system, Cognitive Systems,
Systems for social processes, Arousal/regulatory systems. In
accordance with the reviewed evidence on the involvement of
mGluR5 in MDD and OCD, we propose that mGluR5 activity
might directly be associated with the negative valence system,
which involves the observable factors of fear, threat, sustained
threat, loss, and frustrated non-reward. Thus, as reviewed
studies suggest, antagonistic treatment with mGluR5 should
reduce those observable symptoms. Further, we suggest that
mGluR5 treatment might also be beneficial in “positive valence
disorders” such as addiction and depression, via abnormal
mGluR5 activity on brain structure and function related to
the glutamatergic NMDA receptor that is functionally linked
with mGluR5 and importantly involved in reward learning.
For example, Simonyi et al. (2010) reviewed numerous ani-
mal studies which employed mGluR5 receptor antagonists in
knockout mice to determine the role of mGluR5 in learning
and memory. Inhibitory learning, such as passive avoidance
learning, is a well-established task in animal models that is used
to study hippocampal learning processes, and has been shown
in numerous studies to be dependent on the mGluR5 receptor
(Simonyi et al., 2010). For instance, research demonstrated
hyperexpression of mGluR5 protein in CA3 during short-
and CA1 long-term potentiation in rats (Riedel et al., 2000).
Hyman (2005) presented a biological model of addiction that
incorporates abnormal neural processes of learning and memory
forming the basic elements of addiction. The authors proposed
that long-term potentiation, which includes, alterations in the
availability of glutamate receptors, and regulation of gene expres-
sion as potentially important mechanisms for the drug-induced
alterations found in the abnormal circuits associated with drug
addiction. Finally, the studies on mGluR5 and sleep homeostasis
(Hefti et al., 2013; Ahnaou et al., 2015) suggest an important
role of mGluR5 in RDoC’s arousal and modulatory systems
domain.
Figure 4 summarizes the processes proposed to mediate the
actions of mGluR5 in mood disorders and addiction. The top of
Figure 4 depicts high-density mGluR5 brain regions; amygdala,
hippocampus, striatum, NA, and prefrontal cortex. Psychiatric
syndromes are matched to those regions. mGluR5 activity,
suggested in the amygdala, might mediate primary emotional
arousal, such as anxiety and depression. We have described how
two possible pathways; social functioning, and learning, might
mediate the other processes. Thus, mGluR5 activity has shown
to be involved in learning, and thus, via activity in the hip-
pocampus, NA, and striatum might be involved in memory
and reward, cognitive control and motivation, as also impli-
cated in addiction (See also Figure 3). Finally, we have suggested
how mGluR5 may be related to the social stress response and
social deficits, which might be relevant for a broad range of
psychiatric conditions. Table 2 gives an overview of the RDoC
area of impairment, the associated clinical picture, and mGluR5
involvement.
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FIGURE 4 | Summary of mGluR5 mechanisms.
TABLE 2 | RDoC and mGluR5.
RDoC Sample mechanism Brain regions Possible symptoms of
mGlu5 dysfunction
Psychiatric disorders
Positive valence system mGluR5 mediates
rewarding effects
Striatum, Orbitofrontal
cortex
Drug addiction, adhedonia Nicotine dependence,
Substance misuse, depression
Negative valence system mGluR5 regulates the
response to stress /threat
Amygdala,
ventromedial PFC
Anxiety, decreased stress
tolerance
Depression, OCD, anxiety
disorders
Systems for social processes Weakening of synapse
formation
globally Social deficits Fragile X syndrome, autism,
depression
Arousal/regulatory system mGluR5 mediates brain
excitability
Limbic system Emotional arousal, impaired
circadian rhythms
Anxiety disorders, OCD,
depression
Concluding Remarks
This review described the involvement of mGluR5 in mood
disorders, OCD and addiction, and compared preclinical with
human research, specifically PET research. We thus compared
different methodological approaches, such as animal research,
MRS, and PET studies. We suggest that a strong direct anxi-
olytic effect would be present if mGluR5 antagonistic treatment
was initiated in human clinical trials (RDoC). mGluR5 over-
activity has also been reported in FXS, which is characterized
by important social deficits. As a result, mGluR5 activity may
not just normalize activity in the negative valence systems and
arousal systems, but also attenuate impairments in the systems
for social processes (RDoC). This is of high clinical importance
because poor social functioning is an important outcome of
prevalent psychiatric conditions such as OCD, depression and
addiction, leading to enormous personal suffering and impor-
tant indirect costs for the society. And finally, mGluR5 was
also shown to have a significant involvement in drug addic-
tion, suggested to be mainly caused by increasing the reward
value of the drug. mGluR5 antagonistic intervention would thus
be most effective for the treatment of pathological anxiety and
addiction, and to improve social stress resiliency and social
functioning.
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